Repare Therapeutics Inc ((RPTX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Repare Therapeutics Inc. is conducting a Phase 1/1b clinical study titled ‘Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and preliminary anti-tumor activity of RP-6306, both as a single agent and in combination with RP-3500 or Debio 0123, in patients with advanced solid tumors. The significance of this study lies in its potential to identify new treatment options for these patients.
The interventions being tested include RP-6306, an oral PKMYT1 inhibitor, RP-3500, an oral ATR inhibitor, and Debio0123, an oral WEE1 inhibitor. These drugs are being evaluated for their ability to manage advanced solid tumors.
The study is designed as an interventional, non-randomized, single-group assignment with no masking. Its primary purpose is treatment-focused, aiming to determine the maximum tolerated dose and assess the preliminary anti-tumor activity of the drugs.
The study began on April 9, 2021, and is currently recruiting participants. The last update was submitted on August 1, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The market implications of this study could be significant for Repare Therapeutics Inc., potentially boosting its stock performance if the results are positive. Investor sentiment may also be influenced by the competitive landscape, as advancements in cancer treatment are closely watched by the industry.
The study is ongoing, with further details available on the ClinicalTrials portal.